Performance of Cox proportional hazard models on recovering the ground truth of confounded exposure–response relationships for large‐molecule oncology drugs
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Performance of Cox proportional hazard models on recovering the ground truth of confounded exposure–response relationships for large‐molecule oncology drugs
Authors
Keywords
-
Journal
CPT-Pharmacometrics & Systems Pharmacology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-08-22
DOI
10.1002/psp4.12859
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Application of machine learning based methods in exposure–response analysis
- (2022) Chao Liu et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- The Drug-Dosing Conundrum in Oncology — When Less Is More
- (2021) Mirat Shah et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects
- (2020) Haiqing Isaac Dai et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
- (2020) Sonoko Kawakatsu et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Machine Learning for Survival Analysis
- (2019) Ping Wang et al. ACM COMPUTING SURVEYS
- A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma
- (2019) Rui Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance
- (2018) David Turner et al. CLINICAL CANCER RESEARCH
- Big Data Toolsets to Pharmacometrics: Application of Machine Learning for Time-to-Event Analysis
- (2018) Xiajing Gong et al. CTS-Clinical and Translational Science
- HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- (2017) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
- (2016) Shruti Agrawal et al. Journal for ImmunoTherapy of Cancer
- Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors
- (2014) Amit Garg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
- (2014) Dan Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
- (2014) Valérie F. Cosson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making
- (2012) Jun Yang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now